Published by
The Street
The Street
By PR Newswire SAN DIEGO, Jan. 6, 2022 /PRNewswire/ — Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced it will develop an Omicron-Genotyping COVID-19 test to be used in professional point-of-care settings as part of the company’s ongoing work with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response. The Omicron-specific test will complement Cue’s existing highly-accurate, molecular COVID-19 test, which can detect all known C…